centrosomal protein 135Genealiases: CEP4 · KIAA0635 · MCPH8
Q-omics provides the consensus-scored CEP135 profile across patient tissues and cancer cell-line models. CEP135 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, CEP135 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, CEP135 RNA expression shows 20,722 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCS, HNSC, and UVM as cancer lineages where CEP135 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CEP135 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CEP135 survival associations across molecular data types. CEP135 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CEP135 RNA expression–survival associations across cancer types. High CEP135 expression shows unfavorable associations in KIRP, LIHC, LGG and UVM, but favorable associations in UCS and KIRC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for CEP135 RNA expression.
This table summarizes CEP135 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CEP135. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CEP135 shows lower tumor expression in KICH and higher tumor expression in HNSC, BLCA, LIHC, STAD and CHOL. The HNSC box plot shows higher CEP135 RNA expression in tumor versus normal tissue (log2 FC = +0.932, t-test p < 0.001).
This table shows molecular features associated with CEP135 in patient tissues and cancer cell lines. In patient samples, CEP135 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CEP135 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
